Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 191

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties

Open access
Luistro, Leopoldo, He, Wei, Smith, Melissa, Packman, Kathryn, Vilenchik, Maria, Carvajal, Daisy, Roberts, John, Cai, James, Berkofsky-Fessler, Windy, Hilton, Holly, Linn, Michael, Flohr, Alexander, Jakob-Røtne, Roland, Jacobsen, Helmut, Glenn, Kelli, Heimbrook, David, Boylan, John F.·2009·Cancer Research

Abstract

Notch signaling is an area of great interest in oncology. RO4929097 is a potent and selective inhibitor of γ-secretase, producing inhibitory activity of Notch signaling in tumor cells. The RO4929097 IC50 in cell-free and cellular assays is in the low nanomolar range with >100-fold selectivity with respect to 75 other proteins of various types (receptors, ion channels, and enzymes). RO4929097 inhibits Notch processing in tumor cells as measured by the reduction of intracellular Notch expression by Western blot. This leads to reduced expression of the Notch transcriptional target gene Hes1. RO4929097 does not block tumor cell proliferation or induce apoptosis but instead produces a less transformed, flattened, slower-growing phenotype. RO4929097 is active following oral dosing. Antitumor activity was shown in 7 of 8 xenografts tested on an intermittent or daily schedule in the absence of body weight loss or Notch-related toxicities. Importantly, efficacy is maintained after dosing is terminated. Angiogenesis reverse transcription-PCR array data show reduced expression of several key angiogenic genes. In addition, comparative microarray analysis suggests tumor cell differentiation as an additional mode of action. These preclinical results support evaluation of RO4929097 in clinical studies using an intermittent dosing schedule. A multicenter phase I dose escalation study in oncology is under way. [Cancer Res 2009;69(19):7672–80]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-09-1843

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 191

Metadata

Authors
Luistro, L., He, W., Smith, M., Packman, K., Vilenchik, M., Carvajal, D., Roberts, J., Cai, J., Berkofsky-Fessler, W., Hilton, H., Linn, M., Flohr, A., Jakob-Røtne, R., Jacobsen, H., Glenn, K., Heimbrook, D., & Boylan, J. F.
Venue
Cancer Research
Published
2009-10-01
Volume
69
Issue
19
Pages
7672-7680
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2098456531
Cited by
191
References
3
FWCI
5.76
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties. https://app.cochat.ai/papers/10.1158/0008-5472.can-09-1843
The paper
Luistro, L., He, W., Smith, M., Packman, K., Vilenchik, M., Carvajal, D., Roberts, J., Cai, J., Berkofsky-Fessler, W., Hilton, H., Linn, M., Flohr, A., Jakob-Røtne, R., Jacobsen, H., Glenn, K., Heimbrook, D., & Boylan, J. F. (2009). Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties. Cancer Research. https://doi.org/10.1158/0008-5472.can-09-1843

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.